Cardiovascular and hematologic effects produced by chronic treatment with etoricoxib in normotensive rats

Baracho, Nilo César do Vale; Guizelli, Guilherme Pedrosa; Carmello, Beatriz Leone; Sanches, Danielle de Souza; Silva, Felipe Moraes Costa; Reis, José Marcos dos; Brito, Jarbas de

doi:10.1590/s0102-86502009000300008

Cited by 3 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has potent analgesic and anti-inflammatory effects with higher tolerability and fewer gastrointestinal adverse effects than other non-steroidal anti-inflammatory drugs (NSAIDs). Despite its safety on (Gastrointestinal tract) GIT, cardiovascular problems may occur [ 4 ]. However, the evaluation of such risks is still difficult, as well as the evaluation of possible adverse effects on the cardiovascular system, since there have been no proper studies on the interaction between etoricoxib and azithromycin.…”

Section: Introductionmentioning

confidence: 99%

Ascorbic Acid Ameliorates Cardiac and Hepatic Toxicity Induced by Azithromycin-Etoricoxib Drug Interaction

Hamza

Alaryani

Omara³

et al. 2022

CIMB

View full text Add to dashboard Cite

The complexity of prescribing safe and effective drug therapy is still challenging. Due to the increased number of medications taken by patients, the potential for drug-drug interactions has clinically important consequences. This study focuses on the potential drug-drug interaction between azithromycin and etoricoxib and the possibility of counteracting this adverse reaction by giving ascorbic acid intraperitoneally to male albino rats. Sixty adult male albino rats weighing 150–180 g were used. The rats were allocated into six equal groups. One group was a control, and the others were given azithromycin, etoricoxib, either alone or combination, with one group treated with ascorbic acid and the last group treated with the drug combination and ascorbic acid. Blood samples were collected for measuring AST, ALT, LDH, CK-MB, and troponin alongside antioxidant enzymes and histopathological examination for both liver and heart tissue. The results showed both hepatic and cardiac damage in azithromycin and etoricoxib groups represented by increasing levels of heaptoc enzymes (ALT, AST, LDH, CK-MB, and troponin) with declining antioxidant enzymes and elevation of malondialdehyde and the appearance of hepatic and cardiac toxicities. Upon administration, ascorbic acid ameliorated all the mentioned biochemical parameters. In conclusion, ascorbic acid has great antioxidant capacities and hepatic and cardiac ameliorative effects and can alleviate drug interaction toxicity.

show abstract

Section: Introductionmentioning

confidence: 99%

Ascorbic Acid Ameliorates Cardiac and Hepatic Toxicity Induced by Azithromycin-Etoricoxib Drug Interaction

Hamza

Alaryani

Omara³

et al. 2022

CIMB

View full text Add to dashboard Cite

show abstract

Selective COX-2 Inhibitor Etoricoxib’s Liposomal Formulation Attenuates M2 Polarization of TAMs and Enhances its Anti-metastatic Potential

et al. 2023

View full text Add to dashboard Cite

Etoricoxib Attenuates Effect of Antihypertensives in a Rodent Model of DOCA-Salt Induced Hypertension

Chugh

Gupta

Agarwal

et al. 2013

Clinical and Experimental Hypertension

View full text Add to dashboard Cite

While it is known that non-steroidal anti-inflammatory drugs including selective cyclooxygenase-2 (COX-2) inhibitors influence BP, the exact relationship and underlying mechanisms are still unclear. We investigated the effect of etoricoxib, a selective COX-2 inhibitor on the antihypertensive efficacy of atenolol; beta-blocker, ramipril; angiotensin converting enzyme inhibitor and telmisartan; angiotensin receptor blocker in deoxycorticosterone acetate (DOCA)-salt hypertensive rats, a mineralocorticoid volume expansion model. Etoricoxib attenuated the antihypertensive-induced reduction of systolic (atenolol; P< .001, ramipril; P = .011, telmisartan; P = .003) and mean arterial pressure (atenolol; P < .001, ramipril; P = .032, telmisartan; P = .023). These results demonstrate that COX-2 dependent mechanisms play a significant role in blood pressure regulation, and etoricoxib-induced COX-2 inhibition blunts the therapeutic effect of different classes of antihypertensives in this mineralocorticoid volume expansion model of hypertension.

show abstract

Cardiovascular and hematologic effects produced by chronic treatment with etoricoxib in normotensive rats

Abstract: These data show that the chronic treatment with etoricoxib leads to increase of the MAP, and to important hematological changes which seem to be associated to the hemoconcentration although not producing anatomopathological significant changes.

Cited by 3 publications

References 15 publications

Ascorbic Acid Ameliorates Cardiac and Hepatic Toxicity Induced by Azithromycin-Etoricoxib Drug Interaction

Ascorbic Acid Ameliorates Cardiac and Hepatic Toxicity Induced by Azithromycin-Etoricoxib Drug Interaction

Selective COX-2 Inhibitor Etoricoxib’s Liposomal Formulation Attenuates M2 Polarization of TAMs and Enhances its Anti-metastatic Potential

Etoricoxib Attenuates Effect of Antihypertensives in a Rodent Model of DOCA-Salt Induced Hypertension

Contact Info

Product

Resources

About